Novartis has launched the FocalView app, an ophthalmic digital research platform designed to allow researchers to track disease progression by collecting real-time data reported from consenting patients.
By adapting the design of clinical trials for patients’ daily routines, the app may reduce barriers to study participation, the company said in a press release.
The app will help patients complete assessments and gain feedback on their visual function, including changes over time. It can also provide researchers with real-world, patient-reported data to create more flexible and accessible trial designs.
The app will be tested for efficacy and usability in assessing visual function, including visual acuity and contrast sensitivity, in a prospective, non-interventional study. Researchers will evaluate the app’s ease of use, patient enrollment and ability to obtain documentation for future research, according to the release.
FocalView is available for download in the United States. User consent to contribute to research data will be required before interaction with the tool is allowed.